All analyses
AI analysis

Chemanex Plc: research report

UndervaluedbullishOct 5, 2026

Evidence points bullish because June profitability more than doubled as margins widened sharply. The catch is that 36.5% of trailing earnings came from that one quarter.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bullish

  • June operating margin widened to 32.4% from 19.3%, lifting quarterly operating profit 100.2% year-on-year.
  • Net profit rose 119.7% year-on-year while revenue grew 19.1%, showing that the latest improvement was driven by stronger profitability as well as sales growth.
  • Debt was 3.8% of owners' equity at the March year-end, leaving the balance sheet lightly geared.

Against this. The latest quarter supplied 36.5% of trailing EPS, and using its year-ago margin would lift the current P/E to 14.3 times.

Operating margin
13.0%sector 11.3%
from 15.5% a year earlier
Net margin
3.7%sector 6.6%
from 8.9% a year earlier, revenue -15.3%
Return on equity
4.4%
twelve months to Sep 30, 2026, unaudited
P/E
12.8sector 12.8
earnings Rs 11.69 per share, year to Sep 2026
P/B
0.56sector 1.70
book Rs 266.21 per share
Dividend yield
1.67%sector 1.62%
21.4% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Oct 5, 2026. Sector figures are the median of 29 listed companies in the same sector.

Overview

Chemanex supplies specialist industrial chemicals, raw materials and technical support across Sri Lankan manufacturing end-markets, while also holding strategic and listed investments. The June filing showed a marked improvement in operating profitability and absolute profit, with margins doing more of the work than sales growth alone.

Price performance

At LKR 152 on 2 October 2026, the share had fallen 8.0% over three months against a 6.3% decline in the ASPI. It was at its 52-week low, while recent volatility and trading volume were both above this share's own one-year and 60-day norms, respectively.

The three-year record contains four falls of 15% or more, with the deepest 27% and taking eight months to recover. Liquidity is the practical constraint: median daily turnover was only LKR 49,075, and a LKR 1 million order is more than everything that trades on a typical day (2038% of it).

Valuation

At 11.95 times P/E, the share costs about LKR 12 for every LKR 1 of trailing profit, close to the manufacturing median of 12.08 times. Its 0.53 times P/B means buyers pay about 53 cents for each rupee of net assets, placing it cheaper than 96% of sector peers on that measure. The market-wide assessment is moderately undervalued, scoring 79 of 100 on price against book value, earnings and dividends.

The P/B is more expensive than 55% of days since January 2019, so the apparent discount to sector book values is not equally unusual in Chemanex's own record. Trailing ROE was 4.5%, meaning the business generated about 4.5 cents of profit for each rupee of owners' equity over the twelve months to June 2026.

The 1.6% dividend yield trails the sector median of 3.4%. Dividends were LKR 2.50 for FY2026 after LKR 7.36 in FY2025, although the latest year may be incomplete; the payout ratio was 19.7%, leaving earnings cover of 5.08 times. At this price, the earnings multiple also relies on June contributing 36.5% of trailing EPS: at the year-ago margin, P/E would be 14.3 times.

News and sentiment

Direct company coverage is thin, with no material articles recorded in the past 90 days. The only recent material item was the FY2026 final dividend of LKR 2.50 per share, reported on 26 May; its 1 July 2026 ex-date has passed, so a buyer today does not receive it.

Financials

For the June 2026 quarter, revenue rose 19.1% year-on-year to LKR 273 million, while net profit rose 119.7% to LKR 77 million. Gross margin was 29.9% versus 24.2% a year earlier, operating margin was 32.4% versus 19.3%, and net margin was 28.1% versus 15.2%. In everyday terms, Chemanex retained 28 cents from each rupee of sales after all costs, against 15 cents a year earlier.

Each margin ranked among the company's better June outcomes: gross and net margin were second of seven comparable June quarters, while operating margin was second of six. The LKR 11.9 million gap between operating and net profit was larger than the LKR 9.4 million a year earlier, but was small relative to the LKR 88.6 million operating profit.

Equity attributable to owners stood at LKR 4.6 billion. Shares outstanding were 16.2 million at June 2026, compared with 15.7 million a year earlier, so absolute profit is the cleaner measure of the improvement than EPS alone. The latest filed figures end in June 2026, and no newer company results are present in the news flow.

Risks

The main financial-quality risk is cash conversion. Operating cash flow covered only 0.45 times operating profit in the March 2026 financial year, so less than half of the reported operating profit arrived as cash; this matters because the June profit acceleration is the central support for the current valuation.

Balance-sheet leverage is modest, with debt equal to 3.8% of owners' equity and operating profit covering the interest bill 8.05 times. The current ratio was 13.28 times, meaning short-term assets, including inventory and customer receivables, substantially exceeded bills due within a year.

Chemanex imports chemicals, while the rupee had depreciated 6.3% year-to-date by end-September, creating a cost and working-capital exposure. Manufacturing export conditions also softened in August. Finally, the share is barely traded, making the LKR 49,075 median daily turnover a material constraint for larger positions.

Outlook

As at 5 October 2026, the next defined catalyst is the September 2026 interim filing, expected between 6 and 14 November. It will show whether the June margin improvement continued into the following quarter and refresh the cash-flow and balance-sheet evidence behind the profit increase.

The available data cannot establish the durability of June's unusually large contribution to trailing earnings. The filing will also arrive against a manufacturing backdrop of softer August exports and a weaker rupee, both relevant to a chemicals supplier that sources internationally.

About this report. Generated on Oct 5, 2026 from market data up to Oct 2, 2026, 0 material news articles over 90 days and financials to Jun 30, 2026, and scored 79 of 100 on value (moderately undervalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports